Trial Profile
A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients With Adenovirus Viremia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jul 2021
Price :
$35
*
At a glance
- Drugs Brincidofovir (Primary) ; Cidofovir; Ganciclovir; Ribavirin
- Indications Adenovirus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chimerix
- 09 May 2019 Status changed from recruiting to discontinued, according to a Chimerix media release.
- 14 Aug 2018 Status changed from not yet recruiting to recruiting.
- 16 Jul 2018 Planned primary completion date changed from 30 May 2019 to 30 Sep 2019.